Essential hypertension is associated with decreased insulin clearance and insulin resistance.

Essential hypertension is associated with multiple metabolic abnormalities, among them, hyperinsulinemia. This hyperinsulinemia is attributed to the presence of decreased insulin sensitivity (insulin resistance) with consequent compensatory insulin secretion. We tested the hypothesis that decreased insulin clearance is present in hypertensive subjects and contributes to hyperinsulinemia independently of the degree of insulin resistance. Seventy-five subjects were studied (48 hypertensive and 27 normotensive). Both groups were comparable in terms of age, body fat content, waist-to-hip ratio, and sex distribution. A primed continuous insulin infusion at 40 mU/m2 per minute was performed. Glucose was maintained at baseline levels with the euglycemic clamp technique. Hypertensive subjects were characterized by decreased insulin sensitivity (insulin-mediated glucose uptake: 5.14 +/- 0.28 versus 7.26 +/- 0.61 mg glucose/kg fat-free mass per minute, hypertensive versus normotensive, P = .002), increased insulin levels during the insulin infusions (804 +/- 36 versus 510 +/- 38 pmol/L, hypertensive versus normotensive, P < .001), and decreased insulin metabolic clearance rate (328 +/- 15 versus 521 +/- 30 mL/min per meter squared, hypertensive versus normotensive, P < .001). In an ANCOVA (including sex, degree of obesity, waist-to-hip ratio, and insulin sensitivity as covariates) the differences in insulin metabolic clearance rate between normotensive and hypertensive subjects remained highly significant (P < .001). Insulin metabolic clearance rate was significantly associated with fasting insulin levels. We conclude that essential hypertension is independently associated with decreased insulin metabolic clearance rate in addition to insulin resistance. A low insulin metabolic clearance rate may be a contributory factor to the hyperinsulinemia observed in essential hypertension.

[1]  T. Welborn,et al.  Serum-insulin in essential hypertension and in peripheral vascular disease. , 1966, Lancet.

[2]  H. Parving,et al.  Transcapillary Escape Rate of Albumin and Plasma Volume in Essential Hypertension , 1973, Circulation research.

[3]  M Berman,et al.  A model of the kinetics of insulin in man. , 1974, The Journal of clinical investigation.

[4]  R. Dowell,et al.  Microvascular rarefaction in spontaneously hypertensive rat cremaster muscle. , 1981, The American journal of physiology.

[5]  L. Wilkins.  Hypertension prevalence and the status of awareness, treatment, and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. , 1985, Hypertension.

[6]  H. Halkin,et al.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. , 1985, The Journal of clinical investigation.

[7]  C Cobelli,et al.  The kinetics of insulin in man. II. Role of the liver. , 1987, Diabetes/metabolism reviews.

[8]  E. Ferrannini,et al.  Insulin resistance in essential hypertension. , 1987, The New England journal of medicine.

[9]  G. Reaven,et al.  Resistance to insulin-stimulated-glucose uptake in patients with hypertension. , 1988, The Journal of clinical endocrinology and metabolism.

[10]  P. Tonellato,et al.  Microvascular rarefaction and tissue vascular resistance in hypertension. , 1989, The American journal of physiology.

[11]  G. Reaven,et al.  Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. , 1989, American journal of hypertension.

[12]  J. K. Radder,et al.  In Vivo Relationship Between Insulin Clearance and Action in Healthy Subjects and IDDM Patients , 1990, Diabetes.

[13]  T. O'dorisio.  Panel discussion IX: Clinical application of somatostatin analogs, part I, August 9, 1989 , 1990 .

[14]  R. Stout,et al.  Insulin and atheroma. 20-yr perspective. , 1990, Diabetes care.

[15]  L. Sechi,et al.  Insulinemia and blood pressure. Relationships in patients with primary and secondary hypertension, and with or without glucose metabolism impairment. , 1990, American journal of hypertension.

[16]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[17]  M. Laakso,et al.  High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[18]  G. Reaven.  Resistance to insulin-stimulated glucose uptake and hyperinsulinemia: role in non-insulin-dependent diabetes, high blood pressure, dyslipidemia and coronary heart disease. , 1991, Diabete & metabolisme.

[19]  E A Anderson,et al.  Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. , 1991, The Journal of clinical investigation.

[20]  R. Bergman,et al.  Relationship of insulin clearance and secretion to insulin sensitivity in non‐diabetic Mexican Americans , 1992, European journal of clinical investigation.

[21]  R. Bergman,et al.  Modeling of insulin action in vivo. , 1992, Annual review of physiology.

[22]  R. Torella,et al.  Decreased insulin clearance as a feature of essential hypertension. , 1992, The Journal of clinical endocrinology and metabolism.

[23]  W. Sheu,et al.  Hepatic insulin extraction and insulin clearance in patients with essential hypertension. , 1994, Clinical and experimental hypertension.

[24]  A. Swislocki.  Impaired insulin clearance in essential hypertension. , 1994, Journal of human hypertension.

[25]  A. Scheen,et al.  How to measure insulin clearance. , 1994, Diabetes/metabolism reviews.